Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells

Cell Communication and Signaling

Volumn 13, Issue 1, 2015, Pages

  Selvaraj, Nagarathinam ^a   Kedage, Vivekananda ^a   Hollenhorst, Peter C ^a  

^a Indiana University School of Medicine   (United States)

Author keywords

Cell migration; ERG; ERK; ETS transcription factors; JNK; Mitogen activated protein kinase; P38; Prostate cancer

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1; ERG PROTEIN, HUMAN; ETS1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ARTICLE; BINDING AFFINITY; CELL MIGRATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ERG GENE; ETS GENE; GENE OVEREXPRESSION; IN VITRO STUDY; MAP KINASE ASSAY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; CELL MOTION; COMPARATIVE STUDY; CYTOLOGY; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PROSTATE;

CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; PROSTATE; PROTO-ONCOGENE PROTEIN C-ETS-1; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 84928753728     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-015-0089-7     Document Type: Article

References (58)

1. Messina DN, Glasscock J, Gish W, Lovett M. An ORFeome-based analysis of human transcription factor genes and the construction of a microarray to interrogate their expression. Genome Res. 2004;14:2041-7.
2. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 2010;29:2147-60.
3. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem. 2011;80:437-71.
4. Hollenhorst PC, Jones DA, Graves BJ. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 2004;32:5693-702.
5. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev. 2007;21:1882-94.
6. Odrowaz Z, Sharrocks AD. ELK1 uses different DNA binding modes to regulate functionally distinct classes of target genes. PLoS Genet. 2012;8:e1002694.
7. Charlot C, Dubois-Pot H, Serchov T, Tourrette Y, Wasylyk B. A review of posttranslational modifications and subcellular localization of Ets transcription factors: possible connection with cancer and involvement in the hypoxic response. Methods Mol Biol. 2010;647:3-30.
8. Carlson SM, Chouinard CR, Labadorf A, Lam CJ, Schmelzle K, Fraenkel E, et al. Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3. Sci Signal. 2011;4:rs11.
9. Li QJ, Yang SH, Maeda Y, Sladek FM, Sharrocks AD, Martins-Green M. MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. EMBO J. 2003;22:281-91.
10. Foulds CE, Nelson ML, Blaszczak AG, Graves BJ. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol. 2004;24:10954-64.
11. Ducret C, Maira SM, Dierich A, Wasylyk B. The net repressor is regulated by nuclear export in response to anisomycin, UV, and heat shock. Mol Cell Biol. 1999;19:7076-87.
12. Arai H, Maki K, Waga K, Sasaki K, Nakamura Y, Imai Y, et al. Functional regulation of TEL by p38-induced phosphorylation. Biochem Biophys Res Commun. 2002;299:116-25.
13. Plotnik JP, Budka JA, Ferris MW, Hollenhorst PC. ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells. Nucleic Acids Res. 2014;42:11928-40.
14. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-8.
15. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev. 2011;25:2147-57.
16. Selvaraj N, Budka JA, Jerde TJ, Ferris MW, Hollenhorst PC. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation. Mol Cancer. 2014;13:61.
17. Green SM, Coyne III HJ, McIntosh LP, Graves BJ. DNA binding by the ETS protein TEL (ETV6) is regulated by autoinhibition and self-association. J Biol Chem. 2010;285:18496-504.
18. Kim CA, Phillips ML, Kim W, Gingery M, Tran HH, Robinson MA, et al. Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression. EMBO J. 2001;20:4173-82.
19. Poirel H, Lopez RG, Lacronique V, Della Valle V, Mauchauffe M, Berger R, et al. Characterization of a novel ETS gene, TELB, encoding a protein structurally and functionally related to TEL. Oncogene. 2000;19:4802-6.
20. Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J. 1998;17:1740-9.
21. Janknecht R, Monte D, Baert JL, de Launoit Y. The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA. Oncogene. 1996;13:1745-54.
22. Le Gallic L, Sgouras D, Beal Jr G, Mavrothalassitis G. Transcriptional repressor ERF is a Ras/mitogen-activated protein kinase target that regulates cellular proliferation. Mol Cell Biol. 1999;19:4121-33.
23. Strahl T, Gille H, Shaw PE. Selective response of ternary complex factor Sap1a to different mitogen-activated protein kinase subgroups. Proc Natl Acad Sci U S A. 1996;93:11563-8.
24. Ducret C, Maira SM, Lutz Y, Wasylyk B. The ternary complex factor Net contains two distinct elements that mediate different responses to MAP kinase signalling cascades. Oncogene. 2000;19:5063-72.
25. Mao C, Ray-Gallet D, Tavitian A, Moreau-Gachelin F. Differential phosphorylations of Spi-B and Spi-1 transcription factors. Oncogene. 1996;12:863-73.
26. Yang BS, Hauser CA, Henkel G, Colman MS, Van Beveren C, Stacey KJ, et al. Rasmediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol. 1996;16:538-47.
27. O'Hagan RC, Tozer RG, Symons M, McCormick F, Hassell JA. The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene. 1996;13:1323-33.
28. Janknecht R. Cell type-specific inhibition of the ETS transcription factor ER81 by mitogen-activated protein kinase-activated protein kinase 2. J Biol Chem. 2001;276:41856-61.
29. Maki K, Arai H, Waga K, Sasaki K, Nakamura F, Imai Y, et al. Leukemia-related transcription factor TEL is negatively regulated through extracellular signalregulated kinase-induced phosphorylation. Mol Cell Biol. 2004;24:3227-37.
30. Flory E, Hoffmeyer A, Smola U, Rapp UR, Bruder JT. Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. J Virol. 1996;70:2260-8.
31. Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S, et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene. 2002;21:2309-19.
32. Fowles LF, Martin ML, Nelsen L, Stacey KJ, Redd D, Clark YM, et al. Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling. Mol Cell Biol. 1998;18:5148-56.
33. Hoffmeyer A, Avots A, Flory E, Weber CK, Serfling E, Rapp UR. The GABPresponsive element of the interleukin-2 enhancer is regulated by JNK/SAPKactivating pathways in T lymphocytes. J Biol Chem. 1998;273:10112-9.
34. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science. 1995;269:403-7.
35. Polychronopoulos S, Verykokakis M, Yazicioglu MN, Sakarellos-Daitsiotis M, Cobb MH, Mavrothalassitis G. The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs. J Biol Chem. 2006;281:25601-11.
36. Yang SH, Sharrocks AD, Whitmarsh AJ. Transcriptional regulation by the MAP kinase signaling cascades. Gene. 2003;320:3-21.
37. Tanoue T, Maeda R, Adachi M, Nishida E. Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. EMBO J. 2001;20:466-79.
38. Barsyte-Lovejoy D, Galanis A, Sharrocks AD. Specificity determinants in MAPK signaling to transcription factors. J Biol Chem. 2002;277:9896-903.
39. Whisenant TC, Ho DT, Benz RW, Rogers JS, Kaake RM, Gordon EA, et al. Computational prediction and experimental verification of new MAP kinase docking sites and substrates including Gli transcription factors. PLoS Comput Biol. 2010;6:8.
40. Galanis A, Yang SH, Sharrocks AD. Selective targeting of MAPKs to the ETS domain transcription factor SAP-1. J Biol Chem. 2001;276:965-73.
41. Jacobs D, Glossip D, Xing H, Muslin AJ, Kornfeld K. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. Genes Dev. 1999;13:163-75.
42. Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, et al. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Mol Cancer Res. 2013;11:1349-61.
43. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595-9.
44. Post A, Pannekoek WJ, Ross SH, Verlaan I, Brouwer PM, Bos JL. Rasip1 mediates Rap1 regulation of Rho in endothelial barrier function through ArhGAP29. Proc Natl Acad Sci U S A. 2013;110:11427-32.
45. Politopoulos I, Gibson J, Tapper W, Ennis S, Eccles D, Collins A. Composite likelihood-based meta-analysis of breast cancer association studies. J Hum Genet. 2011;56:377-82.
46. Nelson ML, Kang HS, Lee GM, Blaszczak AG, Lau DK, McIntosh LP, et al. Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP. Proc Natl Acad Sci U S A. 2010;107:10026-31.
47. Whitmarsh AJ, Yang SH, Su MS, Sharrocks AD, Davis RJ. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol. 1997;17:2360-71.
48. Imler JL, Schatz C, Wasylyk C, Chatton B, Wasylyk B. A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum. Nature. 1988;332:275-8.
49. Buchwalter G, Gross C, Wasylyk B. Ets ternary complex transcription factors. Gene. 2004;324:1-14.
50. O'Donnell A, Odrowaz Z, Sharrocks AD. Immediate-early gene activation by the MAPK pathways: what do and don't we know? Biochem Soc Trans. 2012;40:58-66.
51. Cruzalegui FH, Cano E, Treisman R. ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene. 1999;18:7948-57.
52. Seidel JJ, Graves BJ. An ERK2 docking site in the Pointed domain distinguishes a subset of ETS transcription factors. Genes Dev. 2002;16:127-37.
53. Murakami K, Mavrothalassitis G, Bhat NK, Fisher RJ, Papas TS. Human ERG-2 protein is a phosphorylated DNA-binding protein-a distinct member of the ets family. Oncogene. 1993;8:1559-66.
54. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68:320-44.
55. Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we co-target upstream? Sci Signal. 2011;4:pe16.
56. Papatsoris AG, Karamouzis MV, Papavassiliou AG. The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol Cancer Ther. 2007;6:811-9.
57. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239-43.
58. Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S. Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun. 2010;1:100.